A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

267

Participants

Timeline

Start Date

May 10, 2021

Primary Completion Date

June 24, 2023

Study Completion Date

June 24, 2023

Conditions
Obesity
Interventions
DRUG

Tirzepatide

Administered SC

OTHER

Placebo

Administered SC

Trial Locations (18)

2308765

Saiseikai Yokohamashi Tobu Hospital, Yokohama

272-8516

Kohnodai Hospital, National Center for Global Health and Medicine, Ichikawa

791-8026

Saiseikai Matsuyama Hospital, Matsuyama

247-0056

Takai Internal Medicine Clinic, Kamakura-shi

231-0023

Motomachi Takatsuka Naika Clinic, Yokohama

564-0013

Osaka Saiseikai Suita hospital, Suita

565-0853

Medical Corporation Heishinkai OCROM Clinic, Suita-shi

569-1045

Takatsuki Red Cross Hospital, Takatsuki

103-0002

The Institute for Adult Disease, Asahi Life Foundation, Chuo-ku

103-0027

Tokyo-Eki Center-building Clinic, Chuo-ku

103-0028

Medical Corporation Chiseikai Tokyo Center Clinic, Chuo-ku

104-0031

Fukuwa Clinic, Chuo-ku

108-0073

Saiseikai Central Hospital, Minato-Ku

155-0031

Shimokitazawa Tomo Clinic, Setagaya-ku

141 0032

Miho Clinic, Shinagawa-ku

160 0008

Medical Corporation Heishinkai ToCROM Clinic, Shinjuku-ku

990-0834

Yamagata Tokushukai Hospital, Yamagata

530-0001

AMC Nishiumeda Clinic, Osaka

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY